Losses widen on medical insurance and procurement cuts, but brain-computer interface hype lifts shares
First-half loss forecast widens sharply Innovative Medical expects a first-half 2026 net loss of 48–62 million yuan, far wider than last year's 11.4 million yuan loss. The company blames medical insurance policy changes at its Jianhua Hospital and price cuts from centralized drug and consumable procurement. This weakens earnings and pressures the stock price.
This is the first concrete signal of deteriorating fundamentals this period, directly explaining downward pressure on the stock.
Brain-computer interface rally lifts shares Innovative Medical hit multiple daily limit-ups as the brain-computer interface theme surged, driven by the world's first implantable BCI system NEO getting market approval and its first prescription in Shanghai. Sector excitement and IPO progress for peers fueled strong investor demand for related stocks.
This is the main positive force behind the stock's sharp moves, showing how sector hype can override weak fundamentals.
Interim report confirms deep losses and shrinking revenue The 2026 interim report showed a net loss of 52.83 million yuan, 41.47 million wider than last year, with revenue down 15.88% and gross margin collapsing to 1.44%. Operating cash flow turned negative. These numbers confirm the company's core business is under severe pressure.
This is the hard financial confirmation of the earlier loss warning, giving investors the full picture of operational weakness.